This is an open-label, dose-finding study of SRN-927 administered orally on a continuous daily dosing regimen with a PK lead-in period (dose escalation period only). The incidence of dose limiting toxicity (DLT) will be evaluated from Day -7 through the first cycle (28 days) of treatment (35 days total). Depending on safety and tolerability, patients will be assigned sequentially to escalating doses of SRN-927 using standard 3+3 design. All patients will be treated until disease progression, unacceptable toxicity, or patient withdrawal of consent.
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
